4-[(2-oxopiperazinyl)methyl]benzenecarbonitrile | 406496-43-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-[(2-oxopiperazinyl)methyl]benzenecarbonitrile
• 英文别名: 4-[(2-oxopiperazin-1-yl)methyl]benzonitrile
• CAS: 406496-43-3
• 化学式: C₁₂H₁₃N₃O
• mdl: MFCD16732586
• 分子量: 215.255
• InChiKey: NNVNYKNBSLCWCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  56.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(2-oxopiperazinyl)methyl]benzenecarbonitrile 在 吡啶 、 盐酸 作用下， 以 甲醇 为溶剂， 生成 1-[4-(Azetidin-1-yl-imino-methyl)-benzyl]-4-(5-chloro-1H-indole-2-sulfonyl)-piperazin-2-one
  参考文献：
  名称：

  N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors

  摘要：

  A class of N,N-dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-pipeRazin-1-y1methyl)-benzamidiries has been discovered as potent factor Xa inhibitors with desirable in vitro and in vivo anticoagulant activity, but with low oral bioavailability. The 5-chloroindole and 6-chlorobenzo[b]thiophene groups are optimal as the factor Xa S1 binding elements. The strategy of incorporating a side chain on the piperazine nucleus to enhance binding affinity has been examined. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.049
• 作为产物：
  描述：

  4-(4-Cyanobenzyl)-3-oxopiperazine-1-carboxylic acid benzyl ester 在 钯 氢气 、 钯 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以to give 4-[(2-oxopiperazinyl)methyl]benzenecarbonitrile (600 mg, 97%)的产率得到4-[(2-oxopiperazinyl)methyl]benzenecarbonitrile
  参考文献：
  名称：

  Piperazin-2-one amides as inhibitors of factor xa

  摘要：

  本文描述了一种包含有通式(I)或(II)的新型哌嗪-2-酮化合物，包括其药学上可接受的异构体、盐、水合物、溶剂合物和前药衍生物，具有对哺乳动物因子Xa活性的作用。本文还描述了含有这些化合物的组合物。这些化合物和组合物在体内或体外用于预防或治疗哺乳动物中不良血栓形成的病症。

  公开号：

  US20040072860A1

文献信息

• Substituted oxoazaheterocyclyl compounds
  申请人：AVENTIS PHARMACEUTICALS INC.

  公开号：US20040102450A1

  公开（公告）日：2004-05-27

  This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..

  这项发明涉及抑制因子Xa的氧杂杂环化合物，抑制同时抑制因子Xa和因子IIa的氧杂杂环化合物，包含这些化合物的药物组合物，用于制备这些化合物的中间体，直接抑制因子Xa的方法，以及同时直接抑制因子Xa和因子IIa的方法。
• Piperazin-2-one amides as inhibitors of factor xa
  申请人：——

  公开号：US20040072860A1

  公开（公告）日：2004-04-15

  Novel piperazin-2-one containing compounds of general formulae (I) or (II), including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivative having activity against mammalian factor Xa arc described. Compositions containing such compounds are also described. The compounds and the compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.

  通用公式（I）或（II）中含有新颖哌嗪-2-酮类化合物的药物，包括其药学上可接受的异构体、盐、水合物、溶剂合物和具有对哺乳动物凝血因子Xa活性的前药衍生物。还描述了含有这些化合物的组合物。这些化合物和组合物在体外或体内用于预防或治疗哺乳动物中由不良血栓形成特征的疾病。
• [EN] SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS<br/>[FR] COMPOSES OXOAZAHETEROCYCLYLE SUBSTITUE INHIBITEURS DU FACTEUR Xa
  申请人：AVENTIS PHARM PROD INC

  公开号：WO2000032590A1

  公开（公告）日：2000-06-08

  This invention is directed to oxoazaheterocyclyl compounds which inhibit factor Xa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of inhibiting factor Xa.

  本发明涉及抑制因子Xa的氧杂杂环化合物，包括这些化合物的制药组合物，制备这些化合物的中间体和抑制因子Xa的方法。
• PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR XA
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP1322643A1

  公开（公告）日：2003-07-02
• [EN] PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa<br/>[FR] AMIDES PIPERAZINE-2-UN COMME INHIBITEURS DU FACTEUR XA
  申请人：COR THERAPEUTICS INC

  公开号：WO2002026734A1

  公开（公告）日：2002-04-04

  Novel piperazin-2-one containing compounds of general formulae (I) or (II), including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivative having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and the compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.